A panel moderated by Dr Rueth at Best of ASCO 2025 Miami Symposium explored the de-escalation of chemotherapy for certain cancer types, showcasing better responses to targeted therapies.

It discusses advancements in drug antibody conjugates and the future of breast cancer treatment with directed therapies. Progress in targeted agents for triple negative breast cancer and the effectiveness of oestrogen receptor modulators were also highlighted.

The narrative emphasised a shift towards less aggressive surgical approaches as systemic treatments improve.